Treatment Options for Patients with BRCA1/2

Treatment Options for Patients with BRCA1/2

Dr Bekaii-Saab on Frontline Treatment Considerations for BRCA1/2+ Pancreatic CancerПодробнее

Dr Bekaii-Saab on Frontline Treatment Considerations for BRCA1/2+ Pancreatic Cancer

Emerging treatment options for patients with prostate cancerПодробнее

Emerging treatment options for patients with prostate cancer

What's New in Prostate Cancer Treatment? by Heather Cheng, MD, PhDПодробнее

What's New in Prostate Cancer Treatment? by Heather Cheng, MD, PhD

Gene Expression Algorithm for Prioritizing Treatment Options in BRCA1/2 Carriers with Breast CancerПодробнее

Gene Expression Algorithm for Prioritizing Treatment Options in BRCA1/2 Carriers with Breast Cancer

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel ApproachesПодробнее

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel Approaches

What's New in Pancreatic Cancer Treatment by Kim Reiss Binder, MDПодробнее

What's New in Pancreatic Cancer Treatment by Kim Reiss Binder, MD

Real-World Study of Treatment for BRCA1/2 Mutated Advanced Breast CancerПодробнее

Real-World Study of Treatment for BRCA1/2 Mutated Advanced Breast Cancer

Ellen T. Matloff on Prophylactic Treatment Options for BRCA1/2 CarriersПодробнее

Ellen T. Matloff on Prophylactic Treatment Options for BRCA1/2 Carriers

Treatment and Issues For Triple Negative Breast Cancer-May 14, 2020Подробнее

Treatment and Issues For Triple Negative Breast Cancer-May 14, 2020

Triple-Negative Breast Cancer: What's New in Treatment and Research at MBC Patient Forum 2019Подробнее

Triple-Negative Breast Cancer: What's New in Treatment and Research at MBC Patient Forum 2019

Ex vivo retrieval and cryopreservation of oocytes for FP in a BRCA1 mutation carrier...Подробнее

Ex vivo retrieval and cryopreservation of oocytes for FP in a BRCA1 mutation carrier...

Understanding BRCA 1/2 Cancer Risk | Dana-Farber Cancer InstituteПодробнее

Understanding BRCA 1/2 Cancer Risk | Dana-Farber Cancer Institute